Above photo is man-made synthetic “life form”. On this page we will look at different assessments of “Weaponized Mycoplasma”
From that article:
BIOLOGICAL WARFARE RESEARCH AGREEMENT All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Great Britain entered into a secret agreement to create two types of biological weapons (one that would kill and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons. They primarily focused on brucellosis, and they began to weaponize the brucellosis bacteria.
CRYSTALLINE BRUCELLOSIS In a genuine U.S. Senate Study unclassified on February 24, 1977, the title page of this government record reports that George Merck, of the pharmaceutical company, Merck, Sharp and Dohme (which now makes cures for diseases they at one time created), in 1946, reported to the Secretary of War in the United States that his researchers had produced in isolation for the first time, a crystalline bacterial toxin extracted from brucellosis bacteria. The bacterial toxin could be removed in crystalline form and delivered by other vectors (in nature they are delivered within the bacteria). But the factor that is working in the brucellosis is the mycoplasma. Brucellosis is a disease agent that doesn’t kill people; it disables them. But they found that if they had mycoplasma at a certain strength, actually ten to the tenth power, it would develop into AIDS, and the person would die from it within a reasonable period of time because it could bypass our natural human defenses. If it was 108, the person would manifest with chronic fatigue syndrome or fibromyalgia. If it was 107, they would present as wasting; they wouldn’t die, and they wouldn’t be disabled, but they would not be that interested in life, they would waste away (ref. Dr. Donald MacArthur of the Pentagon appearing before a Congressional Committee, June 9, 1969, Department of Defense Appropriations, p.114, 129). Most of us have never heard of brucellosis because it largely disappeared when they began pasteurizing milk, which was the carrier. One salt shaker of this pure disease in a crystalline form could sicken the entire population of Canada. It is absolutely deadly, not in terms of killing the body, but in terms of disabling the body. The advantage of this crystalline disease agent is that it does not show up in blood and tissue tests because the bacteria has disappeared and only the pure disease agent remains. So the doctor thinks that it’s all in your head.
CRYSTALLINE BRUCELLOSIS AND MULTIPLE SCLEROSIS About three years ago in Rochester, New York, a gentleman gave me a document and told me, “I was in the U.S. Army, and I was trained in bacteriological warfare. We were handling a bomb filled with brucellosis, only it wasn’t brucellosis; it was a brucellosis toxin in crystalline form. We were spraying it on the Chinese and North Koreans.” He showed me his certificate listing his training in chemical, biological, and radiological warfare. Then he showed me 16 pages of documents given to him by the U.S. military when he was discharged from the service. It linked brucellosis with multiple sclerosis and stated: “Veterans with multiple sclerosis, a kind of creeping paralysis developing to a degree of 10% or more disability within two years after separation from active service may be presumed to be service-connected for disability compensation. Compensation is payable to eligible veterans whose disabilities are due to service.” In other words, “If you become ill with multiple sclerosis, it is because you were handling this brucellosis and we will give you a pension. Don’t go raising any fuss about it.” The government of the United States, in this official document revealed evidence of the cause of multiple sclerosis, but they didn’t make it known to the public, or to your doctor. In a 1958 report, Drs. Kyger and Haden suggest “…the possibility that multiple sclerosis might be a central nervous system manifestation of chronic brucellosis”. Testing approximately 113 MS patients, they found that almost 95% also tested positive for brucellosis. We have a document from a medical journal which concludes that one out of 500 people who had brucellosis would develop what they called neurobrucellosis, in other words, brucellosis in the brain which settles in the lateral ventricles where the disease multiple sclerosis is basically located.
CONTAMINATION OF CAMP DETRICK LAB WORKERS A report from the New England Journal of Medicine, 1948, Vol.236, p.741 called “Acute Brucellosis Among Laboratory Workers” shows us how actively dangerous this agent is. The laboratory workers were from Camp Detrick, Frederick, Maryland where they were developing biological weapons. Even though these laboratory workers had been vaccinated, wore rubberized suits and masks, and worked through holes in the compartment, many of them came down with this awful disease because it is so absolutely and terrifyingly infectious. The article was written by Lt. Calderone Howell, Marine Corps, Captain Edward Miller, Marine Corps, Lt. Emily Kelly, United States Naval Reserve and Captain Henry Bookman. They were all military personnel engaged in making the disease agent brucellosis into a more effective biological weapon.
TESTING BRUCELLOSIS UPON AN UNSUSPECTING PUBLIC Documented evidence proves that the biological weapons they were developing were tested on the public in various communities without their knowledge or consent. The government knew that crystalline brucellosis would cause disease in humans. Now they needed to determine how it spread, and the best way to disperse it. They tested dispersal methods for Brucella suis and Brucella melitensis at Dugway Proving Ground, Utah, June and September 1952. Probably, 100% of us now are infected with Brucella suis and Brucella melitensis. (ref. p.135, table 4 of Special Virus Cancer Program: Progress Report 8) . Another government document recommended the genesis of open air vulnerability tests, and covert research and development programs to be conducted by the army and supported by the Central Intelligence Agency. At that time, the government of Canada was asked by the government of the United States to cooperate in testing weaponized brucellosis, and Canada cooperated fully with the government of the United States. They wanted to determine (i) if mosquitoes will carry the disease and (ii) if the air will carry it. A government report stated that “…open air testing of infectious biological agents is considered essential to an ultimate understanding of biological warfare potentialities because of the many unknown factors affecting the degradation of micro-organisms in the atmosphere”.
I would encourage all readers to go ahead and click the above link and read this entire article at DJ’s site. Then watch the following videos:
Much more coming shortly…
PATHOGENIC MYCOPLASMA A Common Disease Agent Weaponised
© by Donald W. Scott, MA, MSc © 2001
The Common Cause Medical Research Foundation
190 Mountain Street, Suite 405
Sudbury, Ontario, Canada P3B 4G2
Tel/fax: +1 (705) 670 0180
Most are innocuous and do no harm; only four or five are pathogenic.Mycoplasma fermentans (incognitus strain) probably comes from the nucleus of the Brucella bacterium. This disease agent is not a bacterium and not a virus; it is a mutated form of the Brucella bacterium, combined with a visna virus, from which the mycoplasma is extracted.
The pathogenic Mycoplasma used to be very innocuous, but biological warfare research conducted between 1942 and the present time has resulted in the creation of more deadly and infectious forms of Mycoplasma. Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They “weaponised” it and tested it on an unsuspecting public in North America.
Dr Maurice Hilleman, chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by everybody in North America and possibly most people throughout the world.
Despite reporting flaws, there has clearly been an increased incidence of all the neuro/systemic degenerative diseases since World War II and especially since the 1970s with the arrival of previously unheard-of diseases like chronic fatigue syndrome and AIDS.
According to Dr Shyh-Ching Lo, senior researcher at The Armed Forces Institute of Pathology and one of America’s top mycoplasma researchers, this disease agent causes many illnesses including AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, Type I diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease and collagen-vascular diseases such as rheumatoid arthritis and Alzheimer’s.
Dr Charles Engel, who is with the US National Institutes of Health, Bethesda, Maryland, stated the following at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma…”
I have all the official documents to prove that mycoplasma is the disease agent in chronic fatigue syndrome/fibromyalgia as well as in AIDS, multiple sclerosis and many other illnesses. Of these, 80% are US or Canadian official government documents, and 20% are articles from peer-reviewed journals such as the Journal of the American Medical Association, New England Journal of Medicine and the Canadian Medical Association Journal.The journal articles and government documents complement each other.
Read whole article at Donald W. Scott’s page HERE
Extracted from Nexus Magazine, Volume 8, Number 5 (August-September 2001)
PO Box 30, Mapleton Qld 4560 Australia.firstname.lastname@example.org
Telephone: +61 (0)7 5442 9280; Fax: +61 (0)7 5442 9381
From our web page at: www.nexusmagazine.com
Mycoplasma Stealth Pathogen
image from above link –
Excerpt from that page:
Mycoplasmas are the most primitive form of bacteria, and they are characterized by having a soft exterior membrane rather than a cell wall.
Once thought to be relatively harmless, mycoplasmas are now recognized as being developmentally advanced, complex organisms capable of causing serious and chronic diseases, either by themselves or as cofactors with other pathogenic microbes.
A mycoplasma organism has feelers on its surface that have hooked tips coated with adhesion proteins which enable it to attach itself securely to host cells. Mycoplasmas are highly adaptive stealth pathogens, and a mycoplasma infection can be very difficult to eradicate – especially for people with weakened immune systems.
When mycoplasmas attach themselves to the cells, they generate hydrogen peroxide and super-oxide radicals that cause oxidative stress and damage to the cells and the surrounding tissues.
Mycoplasmas also compete with the cells for a variety of nutrients such as cholesterol, amino acids, sugars, and fatty acids. The resultant loss of nutrients by those cells can impair their ability to function normally.
In addition, mycoplasmas do not have their own DNA, but are capable of hijacking DNA from the cells, thereby causing further damage to them. And by stealing cellular DNA in this manner, mycoplasmas can pass themselves off as being native to the body, so that the immune system does not recognize them as a threat.
The environment preferred by mycoplasmas for colonization is mucous membranes, such as those in the respiratory tract. Mycoplasmas require cholesterol for life support and growth, and there is an abundance of cholesterol in the bronchial tubes.
The cholesterol that a mycoplasma organism steals from the mucous membranes and incorporates into its own exterior membrane acts as yet another cloaking device that enables it to evade the immune system.
Read whole article HERE
And don’t overlook the Sources at end of the article.
While searching around for info on mycoplasma I came upon an interesting corporation named Lonza. Exploring their website I found it packed with Govlish mentality. As an example, here is their message as a “Press Kit“:
Lonza at a Glance
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges.
Claiming detection and curability –
Mycoplasma – Products for Detection and Removal
From above link –
The first article I found from Lonza is dealing with eliminating mycoplasma in lab operations, so they obviously have done much research into the world of mycoplasma. More on Lonza, and their relationship with Technocracy, coming soon. I note that Lonza has extensive knowledge of mycoplasma, and that Lonza will work with players inside the globalist agenda. My statement about that is not a judgment, merely a notation.
Here is their one-hour presentation on detection and elimination of mycoplasma in laboratory work with cell cultures —
Mycoplasmas – Stealth Pathogens
By Leslie Taylor, ND January, 2001
This article by Leslie Taylor also includes the powerful article by Donald Scott, but for the sake of space here, I will separate the two. Please read the whole piece as one article here at her page — http://www.regenerativenutrition.com/content.asp?id=267
Mycoplasmas are a specific and unique species of bacteria – the smallest free-living organism known on the planet. The primary differences between mycoplasmas and other bacteria is that bacteria have a solid cell-wall structure and they can grow in the simplest culture media. Mycoplasmas however, do not have a cell wall, and like a tiny jellyfish with a pliable membrane, can take on many different shapes which make them difficult to identify, even under a high powered electron microscope. Mycoplasmas can also be very hard to culture in the laboratory and are often missed as pathogenic causes of diseases for this reason.
The accepted name was chosen because Mycoplasmas were observed to have a fungi-like structure (Mycology is the study of fungi – hence “Myco”) and it also had a flowing plasma-like structure without a cell wall – hence “plasma”. The first strains were isolated from cattle with arthritis and pleuro-pneumonia in 1898 at the Pasteur Institute. The first human strain was isolated in 1932 from an abscessed wound. The first connection between mycoplasmas and rheumatoid diseases was made in 1939 by Drs. Swift and Brown. Unfortunately, mycoplasmas didn’t become part of the medical school curriculum until the late 1950’s when one specific strain was identified and proven to be the cause of atypical pneumonia, and named Mycoplasma pneumonia. The association between immunodeficiency and autoimmune disorders with mycoplasmas was first reported in the mid 1970s in patients with primary hypogammaglobulinemia (an autoimmune disease) and infection with four species of mycoplasma that had localized in joint tissue. Since that time, scientific testing methodologies have made critical technological progress and along with it, more mycoplasma species have been identified and recorded in animals, humans and even plants.
While Mycoplasma pneumonia is certainly not the only species causing disease in humans, it makes for a good example of how this stealth pathogen can move out of it’s typical environment and into other parts of the body and begin causing other diseases. While residing in the respiratory tract and lungs, Mycoplasma pneumonia remains an important cause of pneumonia and other airway disorders, such as tracheobronchitis, pharyngitis and asthma. When this stealth pathogen hitches a ride to other parts of the body, it is associated with non-pulmonary manifestations, such as blood, skin, joint, central nervous system, liver, pancreas, and cardiovascular syndromes and disorders. Even as far back as 1983, doctors at Yale noted:
“Over the past 20 years the annual number of reports on extrapulmonary symptoms during Mycoplasma (M.) pneumoniae disease has increased. Clinical and epidemiological data indicate that symptoms from the skin and mucous membranes, from the central nervous system, from the heart, and perhaps from other organs as well are not quite uncommon manifestations of M. pneumoniae disease.” (15)
This single stealth pathogen has been discovered in the urogenital tract of patients suffering from inflammatory pelvic disease, urethritis, and other urinary tract diseases (8) It has been discovered in the heart tissues and fluid of patients suffering from cardititis, pericarditis, tachycardia, hemolytic anemia, and other coronary heart diseases.(9, 10, 14) It has been found in the cerebrospinal fluid of patients with meningitis and encephalitis, seizures, ALS, Alzheimer’s and other central nervous system infections, diseases and disorders.(11-13) It has even been found regularly in the bone marrow of children with leukemia.(16- 18) It is amazing that one single tiny bacteria can be the cause of so many seemingly unrelated diseases in humans. But as with all mycoplasma species, the disease is directly related to where the mycoplasma resides in the body and which cells in the body it attaches to or invades.
Today, over 100 documented species of mycoplasmas have been recorded to cause various diseases in humans, animals, and plants. Mycoplasma pneumonia as well as at least 7 other mycoplasma species have now been linked as a direct cause or significant co-factor to many chronic diseases including, rheumatoid arthritis, Alzheimer’s, multiple sclerosis, fibromyalgia, chronic fatigue, diabetes, Crohn’s Disease, ALS, nongonoccal urethritis, asthma, lupus, infertility, AIDS and certain cancers and leukemia, just to name a few.(1-6)
In 1997, the National Center for Infectious Diseases, Centers for Disease Control and Prevention’s journal, Emerging Infectious Diseases, published the article, Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety, by Drs. Baseman and Tully who stated:
“Nonetheless, mycoplasmas by themselves can cause acute and chronic diseases at multiple sites with wide-ranging complications and have been implicated as cofactors in disease. Recently, mycoplasmas have been linked as a cofactor to AIDS pathogenesis and to malignant transformation, chromosomal aberrations, the Gulf War Syndrome, and other unexplained and complex illnesses, including chronic fatigue syndrome, Crohn’s disease, and various arthritides.”
Mycoplasmas, unlike viruses, can grow in tissue fluids (blood, joint, heart, chest and spinal fluids) and can grow inside any living tissue cell without killing the cells, as most normal bacteria and viruses will do. Mycoplasmas are frequently found in the oral and genito-urinary tracts of normal healthy people and are found to infect females four times more often than males, which just happens to be the same incidence rate in rheumatoid arthritis, fibromyalgia, Chronic Fatigue and other related disorders.(7)
Mycoplasmas are parasitic in nature and can attach to specific cells without killing the cells and thus their infection process and progress can go undetected. In some people the attachment of mycoplasmas to the host cell acts like a living thorn; a persistent foreign substance, causing the host’s immune defense mechanism to wage war. This allergic type of inflammation often results in heated, swollen, and painful inflamed tissues, like those found in rheumatoid diseases, fibromyalgia and many other autoimmune disorders like lupus and MS, Crohn’s and others. In such cases the immune system begins attacking itself and/or seemingly healthy cells. Some species of mycoplasmas also have the unique ability to completely evade the immune system. Once they attach to a host cell in the body, their unique plasma and protein coating can then mimic the cell wall of the host cell and the immune system cannot differentiate the mycoplasma from the body’s own host cell.
Mycoplasmas are parasitic in nature because they rely on the nutrients found in host cells including cholesterol, amino acids, fatty acids and even DNA. They especially thrive in cholesterol rich and arginine-rich environments. Mycoplasmas can generally be found in the mucous membrane in the respiratory tract. They need cholesterol for membrane function and growth, and there is an abundance of cholesterol in the bronchial tubes of the respiratory tract. Once attached to a host cell, they then begin competing for nutrients inside the host cells. As nutrients are depleted, then these host cells can begin to malfunction, or even change normal functioning of the cell, causing a chain reaction with other cells (especially within the immune and endocrine systems). Mycoplasmas can even cause RNA and DNA mutation of the host cells and have been linked to certain cancers for this reason. Mycoplasmas can also invade and live inside host cells which evade the immune system, especially white blood cells. Once inside a white blood cell, mycoplasmas can travel throughout the body and even cross the blood/brain barrier, and into the central nervous system and spinal fluid.
Baseman, Joel, et.al., Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety, CDC, Journal of Infectious Diseases, Vol 3, No.1, Feb 1997
S-C. Mycoplasmas and AIDS. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:525-45.
Nicolson G, Nicolson NL. Diagnosis and treatment of mycoplasmal infections in Gulf War illness-CFIDS patients. Intl J Occup Med Immunol Toxicol 1996;5:69-78.
Wear DJ, et.al. Mycoplasmas and oncogenesis:persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 1995;92:10197-201.
Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn’s disease after in-utero measles virus exposure. Lancet 1996;348:516-7.
Taylor-Robinson D. Mycoplasmas in rheumatoid arthritis and other human arthritides. J Clin Pathol 1996;49:781-2.
Dr.Harold Clark, The Intercessor, June 1993, The Road Back Foundation, Delaware OH.
Goulet M, et.al., Isolation of Mycoplasma pneumoniae from the human urogenital tract. J Clin Microbiol 1995;33:2823-5
Daxbock F, et.al., Severe hemolytic anemia and excessive leukocytosis masking mycoplasma pneumonia. Ann Hematol. 2001 Mar;80(3):180-2.
Higuchi ML, et.al., Detection of Mycoplasma pneumoniae and Chlamydia pneumoniae in ruptured atherosclerotic plaques. Braz J Med Biol Res. 2000 Sep;33(9):1023-6.
Socan M, Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis. 2001 Jan 15;32(2):E31-5.
Bencina D, et.al., Intrathecal synthesis of specific antibodies in patients with invasion of the central nervous system by Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis. 2000 Jul;19(7):521-30
Smith R, et.al., Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila). 2000 Apr;39(4):195-201.
Umemoto M, Advanced atrioventricular block associated with atrial tachycardia caused by Mycoplasma pneumoniae infection. Acta Paediatr Jpn. 1995 Aug;37(4):518-20.
Lind K. Manifestations and complications of Mycoplasma pneumoniae disease: a review.Yale J Biol Med. 1983 Sep-Dec;56(5-6):461-8.
Alexander FE. Is Mycoplasma Pneumonia associated with childhood acute lymphoblastic leukemia? Cancer Causes Control. 1997 Sep;8(5):803-11.
Hall JE, Mycoplasma pneumonia in acute childhood leukemia. Pediatr Pulmonol. 1985 Nov-Dec;1(6):333-6.
Murphy WH, Gullis C, Dabich L, Heyn R, Zarafonetis CJD. Isolation of Mycoplasma from leukemic and nonleukemia patients. J Nat Cancer Inst 1970;45:243-51.
How Mycoplasmas Interact in the Body
To understand how mycoplasmas can cause widespread disease, we must first look at the species’ unique properties and interactions with host cells. Unlike viruses and bacteria, mycoplasmas are the smallest free-living and self-duplicating microorganisms, as they don’t require living cells to replicate their DNA and growth.
Mycoplasmas are able to hide inside the cells of the host (patient) or to attach to the outside of host cells. Whether they live inside or outside the host cell, they depend on host cells for nutrients such as cholesterol, amino acids, etc. They compete with the host cells for these nutrients which can interfere with host cell function without killing the host cell.
A mycoplasma has very little DNA of its own, but is capable of using DNA from a host cell. When a mycoplasma takes over the DNA of the host cell, anything can happen – including causing that cell to malfunction in many different ways and/or die, or can cause DNA mutation of the host cell. Mycoplasmas attach to host cells with a tiny arm coated in protein which attaches to the protein coating of host cells. For this reason, antibiotics like tetracycline, which are classified as “protein synthesis inhibitors” are often used against mycoplasma infections. While these antibiotics may block this protein attachment and very slowly starve it from the nutrients it needs from host cells to thrive and replicate, it still takes a healthy immune system to actually kill the mycoplasma for good.
Mycoplasmas are highly adaptable to changing environments and can move anywhere in the body, attaching to or invading virtually any type of cell in the body. The mycoplasma adhesion proteins are very similar to human proteins. Once adhered to the host cell, the mycoplasma can completely mimic or copy the protein cell of the host cell. This can cause the immune system to begin attacking the body’s own cells; an event that happens in all autoimmune diseases.
Certain Mycoplasma species can either activate or suppress host immune systems, and they may use these activities to evade host immune responses. Mycoplasmas can turn on the chain reaction called an immune system response. This includes the stimulation of pro-inflammatory cytokines (chemical messengers of the immune system) which is generally found in most autoimmune and inflammatory diseases and disorders. Mycoplasma can also attach to or invade immune system cells, like the very phagocytes (natural killer cells) that are supposed to kill them. Inside these phagocytes, they can be carried to new locations of inflammation or disease – hidden away like a spy who has infiltrated the defending army. When a mycoplasma attaches to a host cell, it generates and releases hydrogen peroxide and superoxide radicals which cause oxidative stress and damage to the surrounding tissues.
The Main Human Mycoplasma Pathogens
Pathogen / Implicated Disease (1-6)
|Mycoplasma genitalium||Arthritis, chronic nongonococcal urethritis, chronic pelvic inflammatory disease, other urogenital infections and diseases, infertility, AIDS/HIV
|Mycoplasma fermentans||Arthritis, Gulf War Syndrome, Fibromyalgia, Chronic Fatigue Syndrome, Lupus, AIDS/HIV, autoimmune diseases, ALS, psoriasis and Scleroderma, Crohn’s and IBS, cancer, endocrine disorders, Multiple Sclerosis, diabetes
|Mycoplasma salivarium||Arthritis, TMJ disorders, Eye and ear disorders and infections, gingivitis, periodontal diseases including even cavities.|
|Mycoplasma hominis and Ureaplasma urealyticum||Pelvic inflammatory disease, infertility, non-gonococcal urethritis, vaginitis, cervicitis, amnionitis, pyelonephritis, post-partum septicemia, neonatal pneumonia, neonatal conjunctivitis, Reiter’s syndrome, peritonitis, wound infections (C-section), low birth weight infants, and premature rupture of membranes.
|Mycoplasma pneumonia||Pneumonia, asthma, upper and lower respiratory diseases, heart diseases, leukemia, Steven-Johnson syndrome, polyarthritis or septic arthritis, CNS disorders and diseases, urinary tract infections, Crohn’s and Irritable Bowel Syndrome, Guillain-Barr syndrome, polyradiculitis, encephalitis, and septic meningitis, autoimmune diseases.
|Mycoplasma incognitus and
|AIDS/HIV, urogenital infections and diseases, Autoimmune disorders and diseases
|Mycoplasma pirum||Urogenital infections and diseases, AIDS/HIV
|Mycoplasma faucium, M. lipophilum and M. buccale||
Diseases of the gingival crevices and respiratory tract
Krause DC, Taylor-Robinson D. Mycoplasmas which infect humans. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:417-44.
Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975;58:229-42.
Baseman, Joel, et.al., Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. CDC, Journal of Infectious Diseases, Vol 3, No.1, Feb 1997
Blanchard, A., et.al., AIDS-associated mycoplasmas. Ann.Rev.Microbiol. 1994; 48:687-712.
Hawkins, et.al., Association of mycoplasma and human immunodeficiency virus infection: detection of amplified mycoplasma fermentans DNA in blood. J.Infec.Dis. 1992: 165:581-585
Hussain AI, et.al., Mycoplasma penetrans and other mycoplasmas in urine of human immunodeficiency virus-positive children. J Clin Microbiol. 1999 May;37(5):1518-23.
VERY IMPORTANT! Don’t Miss This Article by Donald W. Scott: Chronic Fatigue, Alzheimer’s, Parkinson’s, & Multiple Sclerosis
please go HERE